Please login to the form below

Not currently logged in
Email:
Password:

EMA and FDA calls for innovative approaches for Gaucher disease medicines

The regulatory agencies also urge a similar method for all paediatric diseases

FDA EMARegulators in the US and Europe have outlined a series of proposals, including multi-arm clinical trials, in a bid to improve research into new, innovative treatments for the rare genetic disorder Gaucher disease. 

The joint proposal from the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) also urges the use of innovative methods in developing medicines for diseases in children in general, and encourages medicine developers to extend its clinical data through modelling and simulation techniques.

The agencies are also encouraging the use of multi-arm clinical trials to test the safety and efficacy of medicines developed by different companies in one single trial.

The proposal aims to reduce the number of patients needed for clinical trials, “meaning overall less burden on children and their families, while maintaining high quality standards for medicine development,” the EMA said in a statement.

In addition, the EMA is finalising a reflection paper - expected to be published in the fourth quarter of 2017 - that outlines an efficient approach to allow reliable extrapolation of data to support medicine authorisation.

Article by
Gemma Jones

4th July 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Where is health behaviour change heading?
Cures rely on patient adherence to succeed, and health behaviour change in any non-compliant patient is essential, this post explores where health behaviour change is heading....
Pharma email marketing: Your top 12 tips
Used correctly, email can be one of the most effective and cost-efficient channels for a pharma company to use. To help you get the most from it, we've rounded up...
arrow
Patently unclear?
The challenge of protecting biotech innovations...

Infographics